contact us krjpencn

뉴스현황

Our Events

현재 위치: > 뉴스현황 > Our Events > Guangzhou Magpie Pha...

Guangzhou Magpie Pharmaceuticals was approved by NMPA to start the clinical trials of MN-08

저자:medicilon   업로드:2020-02-26  조회수:

Guangzhou Magpie Pharmaceuticals announced the clinical trials of MN-08, a treatment for Idiopathic Pulmonary Artery Hypertension (IPAH). IPAH is a progressive disease that affects the precapillary pulmonary vasculature. IPAH is a rare and fatal disease which has a high mortality rate.

Guangzhou Magpie Pharmaceuticals was approved by NMPA to start the clinical trials of MN-08 with the help of Medicilon

During the collaboration between Magpie Pharmaceuticals and Medicilon, Medicilon completed the research and development of the GMP manufacturing for API.

이전:Medicilon assisted PA1010 tablets with implied permission for clinical trials

다음에:Previous Medicilon – Extraordinary “2 0 1 9”